Making the journey to school: The gendered and generational aspects of risk in constructing everyday mobilityMURRAY, Lesley.Health, risk & society (Print). 2009, Vol 11, Num 5, pp 471-486, issn 1369-8575, 16 p.Article

In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma modelMARZOLA, Pasquina; DEGRASSI, Anna; ABRAMS, Tinya et al.Clinical cancer research. 2004, Vol 10, Num 2, pp 739-750, issn 1078-0432, 12 p.Article

In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer ModelsHOEFLICH, Klaus P; O'BRIEN, Carol; WEI ZHOU et al.Clinical cancer research (Print). 2009, Vol 15, Num 14, pp 4649-4664, issn 1078-0432, 16 p.Article

Addition of the human interferon β scaffold attachment region to retroviral vector backbones increases the level of in vivo transgene expression among progeny of engrafted human hematopoietic stem cellsMURRAY, Lesley; TRAVIS, Marilyn; LUENS-ABITORABI, Karin et al.Human gene therapy. 2000, Vol 11, Num 14, pp 2039-2050, issn 1043-0342Article

Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathwayCASTANEDO, Georgette M; SHUMEI WANG; HALLADAY, Jason et al.Bioorganic & medicinal chemistry letters (Print). 2010, Vol 20, Num 22, pp 6748-6753, issn 0960-894X, 6 p.Article

Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAF^V600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway SuppressionHOEFLICH, Klaus P; HERTER, Sylvia; STERN, Howard et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 7, pp 3042-3051, issn 0008-5472, 10 p.Article

Progress in ex vivo replication of hemaiopoietic stem cellsYOUNG, Judy C; TUSHINSKI, Robert J; HILL, Beth L et al.Recent research developments in biotechnology & bioengineering. Vol. 1 (1998) ; part II. Recent research developments in biotechnology & bioengineering. 1998, pp 433-447, isbn 81-86481-75-3, 15 p.Book Chapter

Regulation of ERK3/MAPK6 expression by BRAFHOEFLICH, Klaus P; EBY, Michael T; FORREST, William F et al.International journal of oncology. 2006, Vol 29, Num 4, pp 839-849, issn 1019-6439, 11 p.Article

Oncogenic BRAF is required for tumor growth and maintenance in melanoma modelsHOEFLICH, Klaus P; GRAY, Daniel C; MURRAY, Lesley J et al.Cancer research (Baltimore). 2006, Vol 66, Num 2, pp 999-1006, issn 0008-5472, 8 p.Article

Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitorsBENCSIK, Josef R; DENGMING XIAO; WOESSNER, Richard D et al.Bioorganic & medicinal chemistry letters (Print). 2010, Vol 20, Num 23, pp 7037-7041, issn 0960-894X, 5 p.Article

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivoO'FARRELL, Anne-Marie; ABRAMS, Tinya J; SMOLICH, Beverly D et al.Blood. 2003, Vol 101, Num 9, pp 3597-3605, issn 0006-4971, 9 p.Article

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationshipMENDEL, Dirk B; LAIRD, A. Douglas; MURRAY, Lesley J et al.Clinical cancer research. 2003, Vol 9, Num 1, pp 327-337, issn 1078-0432, 11 p.Article

GDC―0449―A potent inhibitor of the hedgehog pathwayROBARGE, Kirk D; BRUNTON, Shirley A; WEI JIA et al.Bioorganic & medicinal chemistry letters (Print). 2009, Vol 19, Num 19, pp 5576-5581, issn 0960-894X, 6 p.Article